pipette
ESEspañol

Alpha-synuclein and neuromelanin converge to promote Parkinsons disease pathology

A. Nicolau-Vera, M. Gonzalez-Sepulveda, J. M. Cladera-Sastre, T. Cuadros, A. Parent, G. Roch, J. Marongiu, B. Huynh, A. A. Mahabadian, F. Su, Z. Chatterton, J. Hoyo, A. Laguna, Y. Fu, G. Halliday, M. Vila

Preprint

In the authors' words

Parkinsons disease (PD) is defined by the preferential degeneration of neuromelanin (NM)-containing dopamine-producing neurons in the substantia nigra (SN), accompanied by intraneuronal inclusions rich in alpha-synuclein (aSYN). However, the mechanistic relationship between NM accumulation and aSYN pathology remains unclear. Here, we reveal a bidirectional pathogenic relationship between aSYN and NM. In human post-mortem midbrain tissue, ventral nigral neurons with high NM content display increased aSYN mRNA expression and are preferentially lost in PD. In a rat model that recapitulates age-dependent, human-like NM accumulation via targeted tyrosinase (TYR) expression, co-expression of aSYN accelerates NM buildup, enhances aSYN oligomerization, and aggravates nigrostriatal degeneration. Mechanistically, aSYN oligomerization in NM-producing rats decreases vesicular dopamine storage and impairs vesicle fusion with the plasma membrane, increasing cytosolic dopamine availability for oxidation into NM. Together, these findings support a pathogenic feedback loop in which elevated aSYN accelerates NM synthesis through disrupted dopamine compartmentalization, while NM accumulation further promotes aSYN aggregation and neuronal loss. This aSYN-NM axis may underlie the preferential vulnerability of pigmented nigral neurons in PD and provide a mechanistic framework for the development of future targeted therapeutics.

Main resultThe abstract does not state a limitation.

Appeared: Sunday, October 25. bioRxiv. Preprint, not yet peer-reviewed.

DOI: 10.64898/2026.10.19.760151